Lundbeck CEO eyes deals to bolster pipeline, complement growth drivers ahead of patent losses
Seattle-based life science company Lundbeck Therapeutics is prioritizing its long-term growth efforts, with recently hired CEO Charl van Zyl looking to facilitate strategic and systematic M&A activity in the new year.
The initiative is prompted by upcoming patent expirations of Lundbeck’s two most profitable treatments, Trintellix/Brintellix and Rexulti. Rexulti, an antipsychotic recently approved by the FDA for Alzheimer’s disease agitation, brought in nearly $500 million from Q1 to Q3 last year. Antidepressant treatment Trintellix/Brintellix is also one of Lundbeck’s top sales brands.
With the patents for both medications set to expire before 2030, van Zyl aims to prioritize new M&A deals that allow Lundbeck to continue developing its pipeline and exercising its strengths. One of the company’s up-and-coming treatments is its migraine medication, Vyepti, which returned positive results in a proof-of-concept study last April.